Kalaris Therapeutics Statistics
Total Valuation
KLRS has a market cap or net worth of $129.20 million. The enterprise value is $12.67 million.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, before market open.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KLRS has 22.93 million shares outstanding. The number of shares has increased by 1,042.87% in one year.
| Current Share Class | 22.93M |
| Shares Outstanding | 22.93M |
| Shares Change (YoY) | +1,042.87% |
| Shares Change (QoQ) | +4.02% |
| Owned by Insiders (%) | 7.35% |
| Owned by Institutions (%) | 16.40% |
| Float | 6.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.64 |
| P/TBV Ratio | 1.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.23, with a Debt / Equity ratio of 0.02.
| Current Ratio | 12.23 |
| Quick Ratio | 12.15 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28.33 |
Financial Efficiency
Return on equity (ROE) is -308.10% and return on invested capital (ROIC) is -116.43%.
| Return on Equity (ROE) | -308.10% |
| Return on Assets (ROA) | -45.11% |
| Return on Invested Capital (ROIC) | -116.43% |
| Return on Capital Employed (ROCE) | -41.20% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.17M |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.90% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -15.90% |
| 50-Day Moving Average | 7.70 |
| 200-Day Moving Average | 6.30 |
| Relative Strength Index (RSI) | 37.02 |
| Average Volume (20 Days) | 83,736 |
Short Selling Information
The latest short interest is 842,687, so 3.68% of the outstanding shares have been sold short.
| Short Interest | 842,687 |
| Short Previous Month | 995,274 |
| Short % of Shares Out | 3.68% |
| Short % of Float | 13.92% |
| Short Ratio (days to cover) | 10.62 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -46.15M |
| Pretax Income | -43.44M |
| Net Income | -43.44M |
| EBITDA | -46.14M |
| EBIT | -46.15M |
| Earnings Per Share (EPS) | -$2.85 |
Full Income StatementBalance Sheet
The company has $117.98 million in cash and $1.45 million in debt, giving a net cash position of $116.53 million or $5.08 per share.
| Cash & Cash Equivalents | 117.98M |
| Total Debt | 1.45M |
| Net Cash | 116.53M |
| Net Cash Per Share | $5.08 |
| Equity (Book Value) | 78.81M |
| Book Value Per Share | 3.44 |
| Working Capital | 109.10M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$38.37 million and capital expenditures -$200,000, giving a free cash flow of -$38.57 million.
| Operating Cash Flow | -38.37M |
| Capital Expenditures | -200,000 |
| Depreciation & Amortization | 13,000 |
| Net Borrowing | 7.50M |
| Free Cash Flow | -38.57M |
| FCF Per Share | -$1.68 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |